Merck & Co., Inc. MRK
Composite 47/100; the shares have moved about 33% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 24/100 — a strong mark against it.
Momentum ranks 80/100 — a strong point in its favour. Balance-sheet strength ranks 55/100 — a slight point in its favour.
Valuation ranks 24/100 — a strong mark against it. Income ranks 37/100 — a moderate mark against it. Growth ranks 41/100 — a slight mark against it.
What the company does Merck & Co. (MRK) is a global healthcare company with two segments: human health pharmaceuticals (Keytruda, Gardasil, Januvia, etc.) and animal health products (livestock and companion animal vaccines/therapeutics).
Key financials ROE 7%, ROA 12%, ROCE 7%; gross margin 76%, operating margin -0.2%, net margin 5%. Revenue growth 1% and EPS growth 8%. Debt/Equity 1.28, net debt/EBITDA 1.62, interest coverage 4.14.
Stock health Sideravia scores: Overall 47 (Weak quality, richly valued, positive momentum). Quality 44, Growth 44, Strength 55, Valuation 22, Momentum 82, Income 37. Piotroski F-Score 4/9, Altman Z 3.70.
Price vs fair value MRK trades at a PREMIUM of 10.10% versus the analyst mean target of 136.85. - Recent cancer-vaccine headlines boosted MRK alongside Moderna’s melanoma trial success (CBS News, Yahoo Finance, Benzinga). - Momentum pillar score of 82 reflects strong 3m/6m/12m returns (87% over 12m). - Valuation percentile of 22 indicates rich pricing vs peers.
Looking forward Forward P/E 48 and PEG 0.39 suggest high near-term earnings expectations. Dividend yield 2.2% with payout 105% may limit dividend growth. Analysts cite oncology pipeline and animal-health strength as key drivers.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.